Healthcare
Technology
Health

Glaukos

$77.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.68 (3.57%) Today
+$2.68 (3.57%) Today

Why Robinhood?

You can buy or sell Glaukos and other stocks, options, ETFs, and crypto commission-free!

About

Glaukos Corporation, also called Glaukos, is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. Read More The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Employees
437
Headquarters
San Clemente, California
Founded
1998
Market Cap
2.71B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
528.84K
High Today
$78.44
Low Today
$74.70
Open Price
$75.21
Volume
135.60K
52 Week High
$78.44
52 Week Low
$26.75

Collections

Healthcare
Technology
Health
Medical
Pharmaceutical
2015 IPO
US
North America

News

Yahoo FinanceMar 15

Pivotal Trial Results for Glaukos’ iStent inject® Published in Leading Ophthalmic Journal

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Study Published in Ophthalmology Demonstrates Significant, Sustained Clinical Benefit and Confirms Favorable Safety Profile for Next-Generation Device Approved by FDA in June 2018 Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investiga...

24
BusinessWireMar 13

Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society (AGS) Annual Meeting on March 14-17, 2019 at the Marriott Marquis Hotel in San Francisco. Glaukos is spons...

3
Yahoo FinanceMar 13

When Should You Buy Glaukos Corporation (NYSE:GKOS)?

Glaukos Corporation (NYSE:GKOS), which is in the medical equipment business, and is based in United States, saw a significant share price rise of over 20% in the past couple of months on the NYSE. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price.

15

Earnings

-$0.19
-$0.11
-$0.02
$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.